Cytokinetics Inc (CYTK) Drops 6.51% on February 08

Equities Staff |

Cytokinetics Inc (CYTK) was one of the Russell 2000's biggest losers for Monday February 08 as the stock slid 6.51% to $6.46, a loss of $-0.45 per share. Starting at an opening price of $6.86 a share, the stock traded between $6.37 and $6.94 over the course of the trading day. Volume was 372,963 shares over 2,492 trades, against an average daily volume of 560,265 shares and a total float of 38.85 million.

The losses send Cytokinetics Inc down to a market cap of $250.95 million. In the last year, Cytokinetics Inc has traded between $13.18 and $5.50, and its 50-day SMA is currently $9.92 and 200-day SMA is $7.87.

Cytokinetics Inc is a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions.

Cytokinetics Inc is based out of South San Francisco, CA and has some 92 employees. Its CEO is Robert I. Blum.

For a complete fundamental analysis analysis of Cytokinetics Inc, check out’s Stock Valuation Analysis report for CYTK. To see the latest independent stock recommendations from’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Emerging Growth

Relevium Technologies Inc.

Relevium Technologies Inc is engaged in the acquisition of products, technologies and businesses relating to musculoskeletal function, specifically Pain Relief, Injury Recovery and Active Performance.

Private Markets


Cloudera offers enterprises a new data platform built on the Apache Hadoop open-source software package. Hadoop is a data-management platform that can consolidate data in a single repository for comprehensive…


Trustify provides trust and safety in both the digital and physical worlds through our vast network of on-demand Private Investigators.By removing the large retainers and high hourly rates that traditional…